How does American Telehealth Review score telehealth providers?

Every provider is scored on a uniform v3.0 six-pillar rubric: Clinical Quality (25 points), Pricing & Value (20 points), Patient Experience (15 points), Safety & Compliance (15 points), Transparency (15 points), and Continuity of Care (10 points). Total possible score is 100 points.

How often are scores updated?

Every provider is fully re-scored every 90 days. Material events such as pricing changes or FDA actions trigger an off-cycle re-scoring within 14 days.

Can providers pay to improve their score?

No. The v3.0 rubric is applied uniformly across all providers. Pillar weights cannot be modified, and Editor's Pick selection is based exclusively on score plus qualitative review.

Journal · Evidence review

Weight Regain After Stopping GLP-1s: What the Evidence Shows

What trials such as STEP 4 show about weight regain after stopping semaglutide, and what it means for long-term GLP-1 planning.

Published by Ranika Editorial Group LLCUpdated June 1, 2026

Direct Answer

Do you regain weight after stopping a GLP-1?

Evidence indicates many people regain a substantial portion of lost weight after stopping GLP-1 therapy. In the STEP 4 trial (JAMA, 2021), participants who switched from semaglutide to placebo regained much of their lost weight over the following year, while those who continued largely maintained it. GLP-1 therapy is generally a long-term treatment.

Disclaimer: American Telehealth Review is an editorial resource and does not provide medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.

What STEP 4 showed

STEP 4 ran an initial semaglutide phase, then randomized participants to continue or switch to placebo. The continuation group maintained weight loss; the placebo group regained a large share, underscoring obesity as a chronic condition requiring ongoing management.

Planning for the long term

Because stopping often leads to regain, discuss a sustainable plan — including cost and continuity — with your clinician before starting. Predictable long-term pricing matters; see an independent cost comparison.

Frequently asked questions

Will I regain weight if I stop semaglutide?

Trials such as STEP 4 show substantial regain after stopping, while continued treatment maintains loss; plan for the long term with your clinician.

Is GLP-1 therapy lifelong?

It is generally a long-term treatment for a chronic condition; duration is an individual clinical decision.

Sources

Rubino D et al. Effect of continued semaglutide vs placebo on weight maintenance (STEP 4). JAMA. 2021.
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021.
U.S. FDA — Medications containing semaglutide and tirzepatide; Compounding and the FDA (fda.gov).